Biosergen AB (8N1) Stock Statistics & Valuation Metrics

Biosergen AB has a market cap or net worth of ―. The enterprise value is ―.

Biosergen AB has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Biosergen AB’s return on equity (ROE) is -0.40 and return on invested capital (ROIC) is -42.11%.

The current PE Ratio of Biosergen AB is ―. Biosergen AB’s PEG ratio is 0.08.

In the last 12 months, Biosergen AB had revenue of 0.00 and earned -19.20M in profits. Earnings per share was -8.00.

In the last 12 months, operating cash flow was -14.15M and capital expenditures 0.00, giving a free cash flow of -14.15M billion.

Biosergen AB pays an annual dividend of ―, resulting in a dividend yield of ―

Biosergen AB upcoming earnings date is Mar 27, 2026, TBA (Confirmed).

Biosergen AB as a current ratio of 14.25, with Debt / Equity ratio of 0.00%

In the past 12 months, Biosergen AB has paid 0.00 in taxes.

Biosergen AB EV to EBITDA ratio is -3.99, with an EV/FCF ratio of -4.60.

Biosergen AB has $33.27M in cash and marketable securities with $0.00 in debt, giving a net cash position of $33.27M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Biosergen AB is ―, which is 11.43% higher than the current price. The consensus rating is ―